From: Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval
CGI-S Rating
Baseline (N = 67) n (%)
Endpoint (n = 67) n (%)
Normal
0
Borderline mentally ill
2 (3.0)
11 (16.4)
Mildly ill
32 (47.8)
31 (46.3)
Moderately ill
25 (37.3)
13 (19.4)
Markedly ill
8 (11.9)
Severely ill
1 (1.5)